<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36958398</PMID><DateCompleted><Year>2023</Year><Month>04</Month><Day>18</Day></DateCompleted><DateRevised><Year>2023</Year><Month>05</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1872-7492</ISSN><JournalIssue CitedMedium="Internet"><Volume>329</Volume><PubDate><Year>2023</Year><Month>May</Month></PubDate></JournalIssue><Title>Virus research</Title><ISOAbbreviation>Virus Res</ISOAbbreviation></Journal><ArticleTitle>Propagation and immunological characterization of coxsackievirus A10 in a serum-free HEK293A cell culture system.</ArticleTitle><Pagination><StartPage>199101</StartPage><MedlinePgn>199101</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">199101</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.virusres.2023.199101</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0168-1702(23)00063-1</ELocationID><Abstract><AbstractText>Coxsackievirus A10 (CVA10) is one of enteroviral pathogens that cause the hand, foot, and mouth disease (HFMD). Since CVA10 was reported to be not easily propagated in the Vero cell culture, a feasible manufacture process for producing formalin-inactivated CVA10 vaccine is urgently needed. Several cell lines that commonly used for viral vaccine production was tested for CVA10 (M2014 strain) culture in this study, and our result showed that CVA10 could be easily propagated in the HEK293A cells. A serum-free HEK293A cell culture system was developed for CVA10 production and the yields have reached over 10<sup>8</sup> TCID<sub>50</sub>/mL. The biochemical and immunogenic properties of CVA10 particles obtained from this serum-free HEK293A culture were identical to our previous study. Two major particles of CVA10 were separated by ultracentrifugation, and only the infectious mature particles were capable of inducing CVA10 neutralizing antibody responses in the mouse immunogenicity studies. Additionally, we found that coxsackievirus A6 and enterovirus A71 could also be easily propagated using this serum-free HEK293A cell culture system. Our results provide a solution to overcome the obstacle in the propagation of CVA10 and facilitate the development of multivalent vaccines for prevention of HFMD.</AbstractText><CopyrightInformation>Copyright Â© 2023 The Author(s). Published by Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lien</LastName><ForeName>Sheng-Chieh</ForeName><Initials>SC</Initials><AffiliationInfo><Affiliation>National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Zhunan Town, Miaoli County, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shen</LastName><ForeName>Yu-Sheng</ForeName><Initials>YS</Initials><AffiliationInfo><Affiliation>National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Zhunan Town, Miaoli County, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Hsiao-Yu</ForeName><Initials>HY</Initials><AffiliationInfo><Affiliation>National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Zhunan Town, Miaoli County, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Shang-Rung</ForeName><Initials>SR</Initials><AffiliationInfo><Affiliation>Institute of Oral Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fang</LastName><ForeName>Chih-Yeu</ForeName><Initials>CY</Initials><AffiliationInfo><Affiliation>National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Zhunan Town, Miaoli County, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Chi-Hsun</ForeName><Initials>CH</Initials><AffiliationInfo><Affiliation>National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Zhunan Town, Miaoli County, Taiwan; Institute of Biotechnology, National Tsing Hua University, Hsinchu, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yi-An</ForeName><Initials>YA</Initials><AffiliationInfo><Affiliation>National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Zhunan Town, Miaoli County, Taiwan; Institute of Biotechnology, National Tsing Hua University, Hsinchu, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chong</LastName><ForeName>Pele Choi-Sing</ForeName><Initials>PC</Initials><AffiliationInfo><Affiliation>National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Zhunan Town, Miaoli County, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Ming-Hsi</ForeName><Initials>MH</Initials><AffiliationInfo><Affiliation>National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Zhunan Town, Miaoli County, Taiwan; Graduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chow</LastName><ForeName>Yen-Hung</ForeName><Initials>YH</Initials><AffiliationInfo><Affiliation>National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Zhunan Town, Miaoli County, Taiwan; Graduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Jen-Ren</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Zhunan Town, Miaoli County, Taiwan; Department of Medical Laboratory Science and Biotechnology, National Cheng Kung University Hospital, Tainan, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Suh-Chin</ForeName><Initials>SC</Initials><AffiliationInfo><Affiliation>Institute of Biotechnology, National Tsing Hua University, Hsinchu, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Chia-Chyi</ForeName><Initials>CC</Initials><AffiliationInfo><Affiliation>National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Zhunan Town, Miaoli County, Taiwan. Electronic address: 010113@nhri.edu.tw.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>03</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Virus Res</MedlineTA><NlmUniqueID>8410979</NlmUniqueID><ISSNLinking>0168-1702</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>16VY3TM7ZO</RegistryNumber><NameOfSubstance UI="C052091">antineoplaston A10</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015164">Vaccines, Inactivated</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006232" MajorTopicYN="Y">Hand, Foot and Mouth Disease</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004770" MajorTopicYN="Y">Enterovirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015164" MajorTopicYN="N">Vaccines, Inactivated</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="Y">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Coxsackievirus A10 (CVA10)</Keyword><Keyword MajorTopicYN="N">HEK293A</Keyword><Keyword MajorTopicYN="N">Hand foot and mouth diseases</Keyword><Keyword MajorTopicYN="N">Inactivated whole virion vaccine</Keyword><Keyword MajorTopicYN="N">Serum-free cell culture</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Chia-Chyi Liu has patent #TWI688652B; CN106661102B; JP6774149B2; WO2015179979A1 licensed to National Health Research Institutes, Taiwan. Hsiao-Yu Lin has patent #TWI688652B; CN106661102B; JP6774149B2; WO2015179979A1 licensed to National Health Research Institutes, Taiwan. Pele Choi-Sing Chong has patent #TWI688652B; CN106661102B; JP6774149B2; WO2015179979A1 licensed to National Health Research Institutes, Taiwan. Yen-Hung Chow has patent #TWI688652B; CN106661102B; JP6774149B2; WO2015179979A1 licensed to National Health Research Institutes, Taiwan.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>12</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>3</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>3</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>4</Month><Day>18</Day><Hour>10</Hour><Minute>16</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>23</Day><Hour>20</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>3</Month><Day>24</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36958398</ArticleId><ArticleId IdType="pmc">PMC10194310</ArticleId><ArticleId IdType="doi">10.1016/j.virusres.2023.199101</ArticleId><ArticleId IdType="pii">S0168-1702(23)00063-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Chahal P.S., Schulze E., Tran R., Montes J., Kamen A.A. Production of adeno-associated virus (AAV) serotypes by transient transfection of HEK293 cell suspension cultures for gene delivery. J. Virol. Methods. 2014;196:163â173. doi: 10.1016/j.jviromet.2013.10.038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jviromet.2013.10.038</ArticleId><ArticleId IdType="pmc">PMC7113661</ArticleId><ArticleId IdType="pubmed">24239634</ArticleId></ArticleIdList></Reference><Reference><Citation>Chong P., Guo M.S., Lin F.H., Hsiao K.N., Weng S.Y., Chou A.H., Wang J.R., Hsieh S.Y., Su I.J., Liu C.C. Immunological and biochemical characterization of coxsackie virus A16 viral particles. PLOS One. 2012;7:e49973. doi: 10.1371/journal.pone.0049973.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0049973</ArticleId><ArticleId IdType="pmc">PMC3511423</ArticleId><ArticleId IdType="pubmed">23226233</ArticleId></ArticleIdList></Reference><Reference><Citation>Chong P., Liu C.C., Chow Y.H., Chou A.H., Klein M. Review of enterovirus 71 vaccines. Clin. Infect. Dis. 2015;60:797â803. doi: 10.1093/cid/ciu852.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciu852</ArticleId><ArticleId IdType="pubmed">25352588</ArticleId></ArticleIdList></Reference><Reference><Citation>Chou A.H., Liu C.C., Chang C.P., Guo M.S., Hsieh S.Y., Yang W.H., Chao H.J., Wu C.L., Huang J.L., Lee M.S., Hu A.Y., Lin S.C., Huang Y.Y., Hu M.H., Chow Y.H., Chiang J.R., Chang J.Y., Chong P. Pilot scale production of highly efficacious and stable enterovirus 71 vaccine candidates. PLOS One. 2012;7:e34834. doi: 10.1371/journal.pone.0034834.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0034834</ArticleId><ArticleId IdType="pmc">PMC3328501</ArticleId><ArticleId IdType="pubmed">22529942</ArticleId></ArticleIdList></Reference><Reference><Citation>Dekevic G., Tasto L., Czermak P., Salzig D. Statistical experimental designs to optimize the transient transfection of HEK 293T cells and determine a transfer criterion from adherent cells to larger-scale cell suspension cultures. J. Biotechnol. 2022;346:23â34. doi: 10.1016/j.jbiotec.2022.01.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbiotec.2022.01.004</ArticleId><ArticleId IdType="pubmed">35085606</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong C., Liu L., Zhao H., Wang J., Liao Y., Zhang X., Na R., Liang Y., Wang L., Li Q. Immunoprotection elicited by an enterovirus type 71 experimental inactivated vaccine in mice and rhesus monkeys. Vaccine. 2011;29:6269â6275. doi: 10.1016/j.vaccine.2011.06.044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2011.06.044</ArticleId><ArticleId IdType="pubmed">21722686</ArticleId></ArticleIdList></Reference><Reference><Citation>Dumont J., Euwart D., Mei B., Estes S., Kshirsagar R. Human cell lines for biopharmaceutical manufacturing: history, status, and future perspectives. Crit. Rev. Biotechnol. 2016;36:1110â1122. doi: 10.3109/07388551.2015.1084266.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/07388551.2015.1084266</ArticleId><ArticleId IdType="pmc">PMC5152558</ArticleId><ArticleId IdType="pubmed">26383226</ArticleId></ArticleIdList></Reference><Reference><Citation>Falsey A.R., Sobieszczyk M.E., Hirsch I., Sproule S., Robb M.L., Corey L., Neuzil K.M., Hahn W., Hunt J., Mulligan M.J., McEvoy C., DeJesus E., Hassman M., Little S.J., Pahud B.A., Durbin A., Pickrell P., Daar E.S., Bush L., Solis J., Carr Q.O., Oyedele T., Buchbinder S., Cowden J., Vargas S.L., Guerreros B.A., Call R., Keefer M.C., Kirkpatrick B.D., Pullman J., Tong T., Brewinski I.M., Benkeser D., Janes H.E., Nason M.C., Green J.A., Kelly E.J., Maaske J., Mueller N., Shoemaker K., Takas T., Marshall R.P., Pangalos M.N., Villafana T., Gonzalez-Lopez A., AstraZeneca AZD1222 Clinical Study Group Phase 3 safety and efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 vaccine. N. Engl. J. Med. 2021;385:2348â2360. doi: 10.1056/nejmoa2105290.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/nejmoa2105290</ArticleId><ArticleId IdType="pmc">PMC8522798</ArticleId><ArticleId IdType="pubmed">34587382</ArticleId></ArticleIdList></Reference><Reference><Citation>European Medicines Agency, 2022. Vaxzevria (previously COVID-19 vaccine AstraZeneca): COVID-19 Vaccine (ChAdOx1-S [recombinant]), https://www.ema.europa.eu/en/medicines/human/EPAR/vaxzevria (accessed 18 March 2023).</Citation></Reference><Reference><Citation>Fang C.Y., Liu C.C. Recent development of enterovirus A vaccine candidates for the prevention of hand, foot, and mouth disease. Expert Rev. Vaccines. 2018;17:819â831. doi: 10.1080/14760584.2018.1510326.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14760584.2018.1510326</ArticleId><ArticleId IdType="pubmed">30095317</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang C.Y., Liu C.C. Novel strategies for the development of hand, foot, and mouth disease vaccines and antiviral therapies. Expert Opin. Drug. Discov. 2022;17:27â39. doi: 10.1080/17460441.2021.1965987.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17460441.2021.1965987</ArticleId><ArticleId IdType="pubmed">34382876</ArticleId></ArticleIdList></Reference><Reference><Citation>GÃ©linas J.F., Azizi H., Kiesslich S., Lanthier S., Perdersen J., Chahal P.S., Ansorge S., Kobinger G., Gilbert R., Kamen A.A. Production of rVSV-ZEBOV in serum-free suspension culture of HEK 293SF cells. Vaccine. 2019;37:6624â6632. doi: 10.1016/j.vaccine.2019.09.044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2019.09.044</ArticleId><ArticleId IdType="pubmed">31548015</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzalez G., Carr M.J., Kobayashi M., Hanaoka N., Fujimoto T. Enterovirus-associated hand-foot and mouth disease and neurological complications in Japan and the rest of the World. Int. J. Mol. Sci. 2019;20:5201. doi: 10.3390/ijms20205201.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms20205201</ArticleId><ArticleId IdType="pmc">PMC6834195</ArticleId><ArticleId IdType="pubmed">31635198</ArticleId></ArticleIdList></Reference><Reference><Citation>Jang M., Pete E.S., Bruheim P. The impact of serum-free culture on HEK293 cells: from the establishment of suspension and adherent serum-free adaptation cultures to the investigation of growth and metabolic profiles. Front. Bioeng. Biotechnol. 2022;10 doi: 10.3389/fbioe.2022.964397.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fbioe.2022.964397</ArticleId><ArticleId IdType="pmc">PMC9485887</ArticleId><ArticleId IdType="pubmed">36147538</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang H., Zhang Z., Rao Q., Wang X., Wang M., Du T., Tang J., Long S., Zhang J., Luo J., Pan Y., Chen J., Ma J., Liu X., Fan M., Zhang T., Sun Q. The epidemiological characteristics of enterovirus infection before and after the use of enterovirus 71 inactivated vaccine in Kunming, China. Emerg. Microbes Infect. 2021;10:619â628. doi: 10.1080/22221751.2021.1899772.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2021.1899772</ArticleId><ArticleId IdType="pmc">PMC8018479</ArticleId><ArticleId IdType="pubmed">33682641</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim S., Bae K.S., Kim J.H., Kang J.H., Choi U.Y. Seroprevalence of neutralizing antibodies against candidate serotypes of enterovirus vaccines among Korean Children. Viral Immunol. 2021;34:62â67. doi: 10.1089/vim.2020.0073.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/vim.2020.0073</ArticleId><ArticleId IdType="pubmed">33030408</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein M., Chong P. Is a multivalent hand, foot, and mouth disease vaccine feasible? Hum. Vaccin. Immunother. 2015;11:2688â2704. doi: 10.1080/21645515.2015.1049780.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2015.1049780</ArticleId><ArticleId IdType="pmc">PMC4685682</ArticleId><ArticleId IdType="pubmed">26009802</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwang T.W., Zeng X., Wang S. Manufacturing of AcMNPV baculovirus vectors to enable gene therapy trials. Mol. Ther. Methods Clin. Dev. 2016;3:15050. doi: 10.1038/mtm.2015.50.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mtm.2015.50</ArticleId><ArticleId IdType="pmc">PMC4729316</ArticleId><ArticleId IdType="pubmed">26858963</ArticleId></ArticleIdList></Reference><Reference><Citation>Le R.A., Jacob D., Transfiguracion J., Ansorge S., Henry O., Kamen A.A. Scalable production of influenza virus in HEK-293 cells for efficient vaccine manufacturing. Vaccine. 2010;28:3661â3671. doi: 10.1016/j.vaccine.2010.03.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2010.03.029</ArticleId><ArticleId IdType="pubmed">20347632</ArticleId></ArticleIdList></Reference><Reference><Citation>Lien S.C., Lu C.C., Shen Y.S., Yang Y.T., Wu S.R., Fang C.Y., Chow Y.H., Liao C.L., Chiang J.R., Liu C.C. Separation and purification of highly infectious enterovirus A71 particles using a strong anion-exchange column. J. Chromatogr. A. 2022;1680 doi: 10.1016/j.chroma.2022.463427.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chroma.2022.463427</ArticleId><ArticleId IdType="pubmed">36029731</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim H., In H.J., Lee J.A., Sik Y.J., Lee S.W., Chung G.T., Choi Y.K., Chung J.K., Cho S.J., Lee J.W. The immunogenicity and protection effect of an inactivated coxsackievirus A6, A10, and A16 vaccine against hand, foot, and mouth disease. Vaccine. 2018;36:3445â3452. doi: 10.1016/j.vaccine.2018.05.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2018.05.005</ArticleId><ArticleId IdType="pubmed">29739716</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu C.C., Wu S.C. Mosquito and mammalian cells grown on microcarriers for four-serotype dengue virus production: variations in virus titer, plaque morphology, and replication rate. Biotechnol. Bioeng. 2004;85:482â488. doi: 10.1002/bit.10918.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/bit.10918</ArticleId><ArticleId IdType="pubmed">14760688</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu C.C., Lian W.C., Butler M., Wu S.C. High immunogenic enterovirus 71 strain and its production using serum-free microcarrier Vero cell culture. Vaccine. 2007;25:19â24. doi: 10.1016/j.vaccine.2006.06.083.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2006.06.083</ArticleId><ArticleId IdType="pubmed">16919374</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu C.C., Guo M.S., Lin F.H., Hsiao K.N., Chang K.H., Chou A.H., Wang Y.C., Chen Y.C., Yang C.S., Chong P.C. Purification and characterization of enterovirus 71 viral particles produced from vero cells grown in a serum-free microcarrier bioreactor system. PLOS One. 2011;6:e20005. doi: 10.1371/journal.pone.0020005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0020005</ArticleId><ArticleId IdType="pmc">PMC3094384</ArticleId><ArticleId IdType="pubmed">21603631</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu C.C., Chow Y.H., Chong P., Klein M. Prospect and challenges for the development of multivalent vaccines against hand, foot and mouth diseases. Vaccine. 2014;32:6177â6182. doi: 10.1016/j.vaccine.2014.08.064.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2014.08.064</ArticleId><ArticleId IdType="pubmed">25218294</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu C.C., Guo M.S., Wu S.R., Lin H.Y., Yang Y.T., Liu W.C., Chow Y.H., Shieh D.B., Wang J.R., Chong P. Immunological and biochemical characterizations of coxsackievirus A6 and A10 viral particles. Antiviral Res. 2016;129:58â66. doi: 10.1016/j.antiviral.2016.02.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2016.02.008</ArticleId><ArticleId IdType="pubmed">26899790</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu C.C., Wu S.C., Wu S.R., Lin H.Y., Guo M.S., Hu A.Y.C., Chow Y.H., Chiang J.R., Shieh D.B., Chong P. Enhancing enterovirus A71 vaccine production yield by microcarrier profusion bioreactor culture. Vaccine. 2018;36:3134â3139. doi: 10.1016/j.vaccine.2017.02.042.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2017.02.042</ArticleId><ArticleId IdType="pubmed">28274636</ArticleId></ArticleIdList></Reference><Reference><Citation>Lohr V., Rath A., Genzel Y., Jordan I., Sandig V., Reichl U. New avian suspension cell lines provide production of influenza virus and MVA in serum-free media: studies on growth, metabolism and virus propagation. Vaccine. 2009;27:4975â4982. doi: 10.1016/j.vaccine.2009.05.083.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2009.05.083</ArticleId><ArticleId IdType="pubmed">19531390</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu Q.B., Zhang X.A., Wo Y., Xu H.M., Li X.J., Wang X.J., Ding S.J., Chen X.D., He C., Liu L.J., Li H., Yang H., Li T.Y., Liu W., Cao W.C. Circulation of coxsackievirus A10 and A6 in hand-foot-mouth disease in China, 2009-2011. PLOS One. 2012;7:e52073. doi: 10.1371/journal.pone.0052073.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0052073</ArticleId><ArticleId IdType="pmc">PMC3525556</ArticleId><ArticleId IdType="pubmed">23272213</ArticleId></ArticleIdList></Reference><Reference><Citation>MiliÃ¡n E., Julien T., Biaggio R., Venereo-Sanchez A., Montes J., Manceur A.P., Ansorge S., Petiot E., Rosa-Calatrava M., Kamen A. Accelerated mass production of influenza virus seed stocks in HEK-293 suspension cell cultures by reverse genetics. Vaccine. 2017;35:3423â3430. doi: 10.1016/j.vaccine.2017.04.065.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2017.04.065</ArticleId><ArticleId IdType="pubmed">28495315</ArticleId></ArticleIdList></Reference><Reference><Citation>Min N., Ong Y.H.B., Han A.X., Ho S.X., Yen E.W.P., Ban K.H.K., Maurer-Stroh S., Chong C.Y., Chu J.J.H. An epidemiological surveillance of hand foot and mouth disease in paediatric patients and in community: a Singapore retrospective cohort study, 2013-2018. PLOS Negl. Trop. Dis. 2021;15 doi: 10.1371/journal.pntd.0008885.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pntd.0008885</ArticleId><ArticleId IdType="pmc">PMC7901731</ArticleId><ArticleId IdType="pubmed">33566802</ArticleId></ArticleIdList></Reference><Reference><Citation>Montagnon B.J., Fanget B., Vincent-Falquet J.C. Industrial-scale production of inactivated poliovirus vaccine prepared by culture of Vero cells on microcarrier. Rev. Infect. Dis. 1984;6:S341âS344. doi: 10.1093/clinids/6.supplement_2.s341.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/clinids/6.supplement_2.s341</ArticleId><ArticleId IdType="pubmed">6740071</ArticleId></ArticleIdList></Reference><Reference><Citation>Nhan L.N.T., Khanh T.H., Hong N.T.T., Van H.M.T., Nhu L.N.T., Ny N.T.H., Nguyet L.A., Thanh T.T., Anh N.T., Hang V.T.T., Qui P.T., Viet H.L., Tung T.H., Ha D.Q., Tuan H.M., Thwaites G., Chau N.V.V., Thwaites L., Hung N.T., van Doorn H.R., Tan L.V. Clinical, etiological and epidemiological investigations of hand, foot and mouth disease in southern Vietnam during 2015-2018. PLOS Negl. Trop. Dis. 2020;14 doi: 10.1371/journal.pntd.0008544.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pntd.0008544</ArticleId><ArticleId IdType="pmc">PMC7451980</ArticleId><ArticleId IdType="pubmed">32804980</ArticleId></ArticleIdList></Reference><Reference><Citation>PÃ©rez Rubio A., Eiros J.M. Cell culture-derived flu vaccine: present and future. Hum. Vaccin. Immunother. 2018;14:1874â1882. doi: 10.1080/21645515.2018.1460297.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2018.1460297</ArticleId><ArticleId IdType="pmc">PMC6149758</ArticleId><ArticleId IdType="pubmed">29672213</ArticleId></ArticleIdList></Reference><Reference><Citation>Prim N., RodrÃ­guez G., Margall N., Del Cuerpo M., Trallero G., Rabella N. Combining cell lines to optimize isolation of human enterovirus from clinical specimens: report of 25 years of experience. J. Med. Virol. 2013;85:116â120. doi: 10.1002/jmv.23426.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.23426</ArticleId><ArticleId IdType="pubmed">23124895</ArticleId></ArticleIdList></Reference><Reference><Citation>Shao H.Y., Hsu H.S., Yu S.L., Wu S.R., Hu K.C., Chang C.K., Liu C.C., Chow Y.H. Immunogenicity of an adeno-vector vaccine expressing the F protein of a respiratory syncytial virus manufactured from serum-free suspension culture. Antiviral Res. 2016;130:27â35. doi: 10.1016/j.antiviral.2016.03.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2016.03.011</ArticleId><ArticleId IdType="pubmed">27001351</ArticleId></ArticleIdList></Reference><Reference><Citation>Simmonds P., Gorbalenya A.E., Harvala H., Hovi T., Knowles N.J., Lindberg A.M., Oberste M.S., Palmenberg A.C., Reuter G., Skern T., Tapparel C., Wolthers K.C., Woo P.C.Y., Zell R. Recommendations for the nomenclature of enteroviruses and rhinoviruses. Arch. Virol. 2020;165:793â797. doi: 10.1007/s00705-019-04520-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00705-019-04520-6</ArticleId><ArticleId IdType="pmc">PMC7024059</ArticleId><ArticleId IdType="pubmed">31980941</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon T., Lewthwarte P., Perera D., Cardosa M.J., McMinn P., Ooi M.H. Virology, epidemiology, pathogenesis and control of enterovirus 71. Lancet Infect. Dis. 2010;10:778â790. doi: 10.1016/s1473-3099(10)70194-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s1473-3099(10)70194-8</ArticleId><ArticleId IdType="pubmed">20961813</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan E., Chin C.S.H., Lim Z.F.S., Ng S.K. HEK293 cell line as a platform to produce recombinant proteins and viral vectors. Front. Bioeng. Biotechnol. 2021;9 doi: 10.3389/fbioe.2021.796991.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fbioe.2021.796991</ArticleId><ArticleId IdType="pmc">PMC8711270</ArticleId><ArticleId IdType="pubmed">34966729</ArticleId></ArticleIdList></Reference><Reference><Citation>Tapia F., Vogel T., Genzel Y., Behrendt I., Hirschel M., Gangemi J.D., Reichl U. Production of high-titer human influenza A virus with adherent and suspension MDCK cells cultured in a single-use hollow fiber bioreactor. Vaccine. 2014;32:1003â1011. doi: 10.1016/j.vaccine.2013.11.044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2013.11.044</ArticleId><ArticleId IdType="pubmed">24269322</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsao K.C., Huang C.G., Huang Y.L., Chen F.C., Huang P.N., Huang Y.C., Lin T.Y., Shih S.R., Chang S.C. Epidemiologic features and virus isolation of enteroviruses in Northern Taiwan during 2000-2008. J. Virol. Methods. 2010;165:330â332. doi: 10.1016/j.jviromet.2010.03.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jviromet.2010.03.001</ArticleId><ArticleId IdType="pubmed">20214926</ArticleId></ArticleIdList></Reference><Reference><Citation>van Doremalen N., Lambe T., Spencer A., Belij-Rammerstorfer S., Purushotham J.N., Port J.R., Avanzato V.A., Bushmaker T., Flaxman A., Ulaszewska M., Feldmann F., Allen E.R., Sharpe H., Schulz J., Holbrook M., Okumura A., Meade-White K., PÃ©rez-PÃ©rez L., Edwards N.J., Wright D., Bissett C., Gilbride C., Williamson B.N., Rosenke R., Long D., Ishwarbhai A., Kailath R., Rose L., Morris S., Powers C., Lovaglio J., Hanley P.W., Scott D., Saturday G., de Wit E., Gilbert S.C., Munster V.J. ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques. Nature. 2020;586:578â582. doi: 10.1038/s41586-020-2608-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2608-y</ArticleId><ArticleId IdType="pmc">PMC8436420</ArticleId><ArticleId IdType="pubmed">32731258</ArticleId></ArticleIdList></Reference><Reference><Citation>Vlecken D.H., Pelgrim R.P., Ruminski S., Bakker W.A., van der Pol L.A. Comparison of initial feasibility of host cell lines for viral vaccine production. J. Virol. Methods. 2013;193:28â41. doi: 10.1016/j.jviromet.2013.04.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jviromet.2013.04.020</ArticleId><ArticleId IdType="pubmed">23684847</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang M., Yan J., Zhu L., Wang M., Liu L., Yu R., Chen M., Xun J., Zhang Y., Yi Z., Zhang S. The establishment of infectious clone and single round infectious particles for Coxsackievirus A10. Virol. Sin. 2020;35:426â435. doi: 10.1007/s12250-020-00198-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12250-020-00198-2</ArticleId><ArticleId IdType="pmc">PMC7462955</ArticleId><ArticleId IdType="pubmed">32144688</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu C.Y., Lin Y.W., Kuo C.H., Liu W.H., Tai H.F., Pan C.H., Chen Y.T., Hsiao P.W., Chan C.H., Chang C.C., Liu C.C., Chow Y.H., Chen J.R. Inactivated enterovirus 71 vaccine produced by 200-l scale serum-free microcarrier bioreactor system provides cross-protective efficacy in human scarb2 transgenic mouse. PLOS One. 2015;10 doi: 10.1371/journal.pone.0136420.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0136420</ArticleId><ArticleId IdType="pmc">PMC4543551</ArticleId><ArticleId IdType="pubmed">26287531</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu S.C., Liu C.C., Lian W.C. Optimization of microcarrier cell culture process for the inactivated enterovirus type 71 vaccine development. Vaccine. 2004;22:3858â3864. doi: 10.1016/j.vaccine.2004.05.037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2004.05.037</ArticleId><ArticleId IdType="pubmed">15364432</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Q., Ding J., Cao J., Huang Q., Hong C., Yang B. Epidemiological and etiological characteristics of hand, foot, and mouth disease in Wuhan, China from 2012 to 2013: outbreaks of coxsackieviruses A10. J. Med. Virol. 2015;87:954â960. doi: 10.1002/jmv.24151.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.24151</ArticleId><ArticleId IdType="pubmed">25754274</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan J., Xu W.W., Jiang S., Yu H., Poon H.F. The scattered twelve tribes of HEK293. Biomed. Pharmacol. J. 2018;11:621â623. http://biomedpharmajournal.org/?p=20696 (accessed 18 March 2023)</Citation></Reference><Reference><Citation>Zhang J., Xu D., Liu H., Zhang M., Feng C., Cong S., Sun H., Yang Z., Ma S. Characterization of coxsackievirus A10 strains isolated from children with hand, foot, and mouth disease. J. Med. Virol. 2022;94:601â609. doi: 10.1002/jmv.27268.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.27268</ArticleId><ArticleId IdType="pubmed">34387895</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao H., Yang T., Yue L., Li H., Xie T., Xiang H., Wang J., Wei X., Zhang Y., Xie Z. Comparative analysis of the biological characteristics of three CV-A10 clones adaptively cultured on Vero cells. J. Med. Virol. 2022;94:3820â3828. doi: 10.1002/jmv.27796.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.27796</ArticleId><ArticleId IdType="pubmed">35437759</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>